本文選題：貝伐單抗 + 化療��； 參考：《中國(guó)臨床藥理學(xué)雜志》2015年15期

【摘要】：目的評(píng)價(jià)貝伐單抗聯(lián)合化療治療復(fù)發(fā)性卵巢癌的臨床療效及安全性。方法回顧性分析我院收治的37例復(fù)發(fā)性卵巢癌患者的臨床資料,所有患者接受至少2個(gè)周期的貝伐單抗聯(lián)合化療方案(7.5 mg·kg-1貝伐單抗+0.9%氯化鈉250 m L靜脈滴注60 min),并在化療方案開(kāi)始前1 h輸注完畢。按實(shí)體腫瘤療效評(píng)價(jià)標(biāo)準(zhǔn)(RECIST)和血清糖類(lèi)癌癥抗原125(CA125)標(biāo)準(zhǔn)分析患者的客觀有效率,同時(shí)分析患者的生存時(shí)間及不良反應(yīng)發(fā)生率。結(jié)果治療后,患者的客觀有效率為32.4%(RECIST標(biāo)準(zhǔn))和43.2%(CA125標(biāo)準(zhǔn))、中位無(wú)疾病進(jìn)展生存時(shí)間為5.4個(gè)月。2例患者達(dá)到完全緩解,無(wú)疾病進(jìn)展生存時(shí)間分別為10.0個(gè)月和11.2個(gè)月。血液學(xué)不良反應(yīng)主要為Ⅰ~Ⅱ級(jí)中性粒細(xì)胞減少和血小板減少。非血液學(xué)不良反應(yīng)主要為Ⅰ~Ⅱ級(jí)惡心嘔吐,腹瀉和高血壓。結(jié)論貝伐單抗聯(lián)合化療治療復(fù)發(fā)性卵巢癌的臨床療效確切,可作為復(fù)發(fā)性卵巢癌的備選治療方案。
[Abstract]:Objective to evaluate the efficacy and safety of bevacizumab combined with chemotherapy in the treatment of recurrent ovarian cancer. Methods the clinical data of 37 patients with recurrent ovarian cancer in our hospital were retrospectively analyzed. All patients received at least 2 cycles of bevacizumab combined with 7.5 mg kg-1 bevacizumab 0.9% sodium chloride 250ml intravenously for 60 mins, and were infused 1 hour before the start of chemotherapy. The objective effective rate of patients was analyzed according to the criteria of solid tumor efficacy evaluation (RECIST) and serum carbohydrate cancer antigen 125 (CA125). The survival time and the incidence of adverse reactions were also analyzed. Results after treatment, the objective effective rate was 32.4%(RECIST standard and 43.2%(CA125 criterion. The median survival time of disease free progression was 5.4 months. The survival time of disease free progression was 10.0 and 11.2 months, respectively. Hematological adverse reactions were mainly grade 鈪，

本文編號(hào)：1818850